I'm a Pathologist. Ozempic & Mounjaro Aren't Actually Weight Loss Drugs.
A physician and pathologist argues that GLP-1 drugs like Ozempic and Mounjaro act on a body-wide signal, not just appetite, and explains the habits he says must go with them.
With Dr. Amin Hedayat (MD)
Key moments
Tap a moment to play the video from there.
- 0:00The puzzle of one drugHedayat describes a diabetes drug that was followed by weight loss and reported changes in the heart, kidneys, sleep and periods, and asks how one medication could do all of that.
- 2:30Where GLP-1 came fromHe explains GLP-1 as a gut hormone that tells the body to release insulin only when blood sugar is high, and says early drug makers focused on the blood sugar half of the story.
- 4:05Heart benefits before weight lossHe says heart protection appeared within weeks in a major study, before people lost meaningful weight, which he takes as a sign that weight is not the cause of the other benefits.
- 5:07GLP-1 as a master signalHedayat walks through the organs he says the signal speaks to, including pancreas, liver, stomach, brain and blood vessels, and notes that only one message concerns appetite.
- 7:42What turns the signal downHe names ultra-processed food, chronic inflammation and insulin resistance as three reasons he says the natural signal fades, and compares it to ignoring a smoke alarm.
- 9:45The hype and doom mythsHe criticizes the miracle crowd and the poison crowd, and gives his view on muscle loss, thyroid cancer concerns and the claim that using help is cheating.
- 13:20The bridge, not the destinationHedayat says the drug is a bridge and that people who build food, movement and sleep habits while on it tend to keep their results.
- 13:51Five foundationsHe covers protein, strength training, side effect comfort measures, tracking waist, strength and labs over scale weight, and keeping habits, repeatedly deferring specifics to a physician.
- 18:30Trials he citesHe describes SELECT for heart events, FLOW for kidneys and a 2024 sleep apnea study, and says the hormone and cycle findings are less solid.
- 20:34Companion guide and communityHe offers a free referenced guide and promotes his paid education community, stating that it is education and not medical care.
What the video says
Hedayat, who describes himself as a triple board certified physician and assistant clinical professor, argues that the GLP-1 class of drugs is misunderstood when it is called a weight loss treatment. He opens with a puzzle: a drug first approved in 2005 for type 2 diabetes was followed by reports of weight loss, lower blood pressure, better sleep and more regular periods. He says it took about 20 years to see that GLP-1, a hormone released by the gut after eating, works as a master signal that reaches the pancreas, liver, stomach, brain, inflammatory cells and blood vessels at once.
A central point for him is timing. He says heart benefits appeared within weeks in a major trial, before meaningful weight loss, so in his view weight loss and the other effects share an upstream cause. He then describes three things he says turn the natural signal down: ultra-processed food, chronic inflammation and insulin resistance. On his account, the drug turns the volume back up from outside while those underlying causes remain.
The second half is built around a bridge metaphor. Hedayat says the drug is a bridge, not the destination, and he criticizes two camps: a hype crowd who treat the shot as the whole answer, and a doom crowd. He responds to concerns about muscle loss, thyroid cancer and the idea that medical help is cheating, giving his own view on each. He then lists five foundations he says help people keep results: protein, strength training, managing side effects with a physician, tracking measures beyond the scale, and lasting habits. He stresses that dosing, continuing or stopping are decisions for the prescribing physician.
Near the end he cites the SELECT, FLOW and sleep apnea studies, and says the evidence on cycles and hormones in women with PCOS (which he calls PMOS) rests on smaller studies. The video closes with promotion of a free companion guide and his paid education community, which he says is not medical care. No specific drug is discussed by generic name.
“The drug is technically a bridge. It's not the destination.”
What this video doesn’t settle
- The video does not name specific drugs or doses, so its claims are about the GLP-1 class as Hedayat describes it, not any single product.
- The study results are Hedayat's summary on screen, with no data shown, and he does not discuss their limits beyond saying the cycle and hormone findings come from smaller studies.
- His claim that habits help people keep results after stopping the drug is stated as his view, with no study cited for it.
Questions this video answers
Why does Dr. Hedayat say Ozempic and Mounjaro are not weight loss drugs?
He argues they raise the activity of GLP-1, a signal the gut sends after eating that reaches many organs, and that appetite is only one of its messages. He points to heart benefits arriving within weeks, before weight loss, as support.
What does Hedayat mean by the drug being a bridge?
He says the medication, for those who use it, helps cross to a destination built from food quality, movement, sleep and lower inflammation. He says people who treat the drug as the destination lose their results when it stops.
What are Hedayat's five foundations for people on GLP-1 medication?
He lists protein, strength training, handling side effects with a physician, tracking signals beyond the scale, and keeping lasting habits. He says exact protein amounts, exercise type and dosing should be set with a doctor or dietitian.
Which studies does Hedayat cite in this video?
He cites SELECT (New England Journal of Medicine, 2023), which he says involved more than 17,000 people and about 20% fewer major heart events. He also cites FLOW (2024), with a 24% reduction in kidney failure and death, and a 2024 sleep apnea study.
Video by Dr. Amin Hedayat, MD on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
